|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
100 项与 TIM1 x Tubulin 相关的临床结果
100 项与 TIM1 x Tubulin 相关的转化医学
0 项与 TIM1 x Tubulin 相关的专利(医药)